Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.53 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941678 | 1.00 | CA12 (0.53) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL847600 | 0.82 | CA12 (0.57) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL1054493 | 0.74 | CA12 (0.57) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL9372428 | 0.73 | CA12 (0.47) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL16896766 | 0.73 | CA12 (0.47) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL9096468 | 0.72 | CA12 (0.46) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL7209185 | 0.71 | NR3C1 (0.44) | CA12CA9 | |
| SCHEMBL1052080 | 0.71 | CA12 (0.59) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL23272041 | 0.71 | HSD17B10 (0.33) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL29947955 | 0.71 | HSD17B10 (0.33) | CA12CA9BRD4BRPF1KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | claimed |
| EP-1133474-A4 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | claimed |
| EP-1181341-B1 | LUMINESCENT 4-TRIFLUOROMETHYL-2-QUINOLONES WITH LONG-WAVE UV-ABSORPTION AND THE USE THEREOF | URAY GEORG (AT) | 2004-10-27 | — | — | EP | claimed |
| US-6635759-B2 | Used as luminescent marker for peptides, proteins, RNA and DNA, as complexing agent | Uray, Georg (AT) | 2003-10-21 | — | — | US | claimed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | claimed |
| US-20020058793-A1 | Luminescent 4-trifluoromethy1-2-quinolones with long wave UV absorption and their use | AGILENT TECHNOLOGIES, INC. | 2002-05-16 | — | — | US | claimed |
| EP-1181341-A2 | LUMINESCENT 4-TRIFLUOROMETHYL-2-QUINOLONES WITH LONG-WAVE UV-ABSORPTION AND THE USE THEREOF | Uray, Georg (AT) | 2002-02-27 | — | — | EP | claimed |
| EP-1133474-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-19 | — | — | EP | claimed |
| WO-2000066680-A2 | LUMINESCENT 4-TRIFLUOROMETHYL-2-QUINOLONES WITH LONG-WAVE UV-ABSORPTION AND THE USE THEREOF | URAY GEORG (AT) | 2000-11-09 | — | — | WO | claimed |
| WO-2000034244-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-15 | — | — | WO | claimed |
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204452-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-11-29 | — | — | US | disclosed |
| WO-2000034244-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5972961-A | ANTIISCHEMIC AGENTS; ANTICONVULSANTS; HEADACHES; SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999009983-A1 | 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0707569-A1 | 4-AMINO-2-QUINOLINONE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995000488-A1 | 4-AMINO-2-QUINOLINONE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | CA12 3122/4885CA9 3988/4885BRD4 4/4885 |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | CA12 3122/4885CA9 3988/4885BRD4 4/4885 |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | CA12 3122/4885CA9 3988/4885BRD4 4/4885 |
| US-20020058793-A1 | Luminescent 4-trifluoromethy1-2-quinolones with long wave UV absorption and their use | CYP4F2, CYP4F12, CRY1 | CA12 257/4885CA9 382/4885BRD4 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.